We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immunization with truncated sequence of Telomerase Reverse Transcriptase induces a specific antitumor response in vivo.
- Authors
Jian Qiu; Guo-Wei Li; Yan-Fang Sui; Yu-Jing Sun; Ya-Yu Huang; Shao-Yan Si; Wei Ge
- Abstract
To select the MHC-I-binding epitope-rich sequence of mice telomerase reverse transcriptase (mTERT) and study the antitumor immune response induced by truncated TERT through mRNA-transfected dendritic cells (DCs) immunization in mice. The MHC-I-binding epitopes of TERT were predicted using bioinformatics software. The selected sequence of TERT (Truncated mTERT, TERTt, mTERT cDNA 1776 bp-2942 bp encoding 584 aa-969 aa) was cloned from B16 mouse melanoma cells and inserted into pBluescriptIIKS(+) plasmid downstream of the T7 promoter. TERTt RNA was prepared through in vitro transcription. Bone marrow-derived DCs were electroporated with TERTt RNA and used to immunize syngeneic naïve mice. The quantity and cytotoxic activity of TERT-specific cytotoxic T lymphocytes (CTLs) in mice spleen were evaluated using IFN-γ enzyme-linked immunospot (ELISPOT) and Lactate dehydrogenase release assay. The immunoprophylactic effects against TERT positive tumor induced by TERTt RNA transfected DC in vivo were evaluated through an immunized-challenged mouse model. TERTt was cloned and in vitro transcribed into TERTt mRNA. As shown in FCM analysis, the efficiency of DC electroporation is 35.1% (29.7-41.2%). After electroporation, a subtle increase of costimulator and MHC-II molecules were expressed on the cell surface. Immunization of TERTt mRNA transfected DCs induced IFN-γ-secreting CTLs which manifested specific cytotoxic activity against TERT-positive target cells. In a cancer mouse model, vaccination of TERTt mRNA-transfected DCs suppressed the growth of TERT positive tumors (p=0.001) and prolong the survival time of tumor-bearing animals (p=0.029). TERTt evokes an antitumor immune response in vivo which is targeted to TERT. TERTt can be used as an antigeneic sequence to produce anti-TERT tumor vaccine.
- Subjects
IMMUNIZATION; REVERSE transcriptase; LYMPHOCYTES; LACTATE dehydrogenase; TUMORS
- Publication
Acta Oncologica, 2007, Vol 46, Issue 7, p961
- ISSN
0284-186X
- Publication type
Article
- DOI
10.1080/02841860601166941